<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zarifyan, Alla</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sabatine, Marc S.</style></author><author><style face="normal" font="default" size="100%">Yeh, Robert W.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Continued Dual Antiplatelet Therapy Beneficial in PEGASUS-TIMI 54 and DAPT Trials</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-04-24 09:14:01</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">PEGASUS-TIMI 54 and DAPT trials demonstrated that dual antiplatelet therapy reduced the risk of cardiovascular death, myocardial infarction, or stroke among patients with a history of myocardial infarction, and reduced the risk of ischemic events in patients receiving coronary stents when compared with treatment with aspirin alone but is associated with significantly increased risk of bleeding complications.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>